Open-Label Psilocybin

This open-label, Phase Ib clinical trial (n=50) will investigate the safety, feasibility, and tolerability of a single dose of oral psilocybin (25mg) in individuals with functional impairment due to psychiatric symptoms, including mood, anxiety, trauma, or addiction.

Conducted by Yale University and the Usona Institute, the study aims to assess whether psilocybin can lead to statistically significant reductions in psychiatric symptoms and improvements in functional status. Participants will be followed up at 1, 4, and 6 weeks post-dosing, with optional long-term assessments at 3, 6, and 12 months.

This trial will use a single treatment arm, and all participants will receive the psilocybin dose without any blinding. The study seeks to address limitations of previous research by including a diverse population with various comorbid conditions, reflecting real-world clinical scenarios.

Topic Anxiety Addiction
Compound Psilocybin
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Yale University
The Yale Psychedelic Science Group was established in 2016.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.